Last updated: March 2, 2026
What is the Drug with NDC 24658-0781?
NDC 24658-0781 corresponds to Rilzabrutinib (PRN2246), developed by Principia Biopharma. It is an oral Bruton's tyrosine kinase (BTK) inhibitor designed for autoimmune diseases, notably immune thrombocytopenia (ITP). Clinical development is ongoing, with initial trials showing promise.
Market Context and Key Competitors
Therapeutic Area: Autoimmune Disease (ITP)
- Current treatments: Thrombopoietin receptor agonists (e.g., eltrombopag, romiplostim), corticosteroids, immunosuppressants.
- Market size: The global ITP market was valued at approximately $1.3 billion in 2021. Expected Compound Annual Growth Rate (CAGR): 8%, driven by unmet needs and new therapies.
Competitive Landscape
| Drug Name |
Class |
Approval Status |
2022 Sales (USD millions) |
Key Features |
| Eltrombopag (Promacta) |
TPO receptor agonist |
Approved |
300 |
Oral, used for ITP |
| Romiplostim (Nplate) |
TPO receptor agonist |
Approved |
600 |
Injectable, first approved biologic for ITP |
| Avatrombopag (Doptelet) |
TPO receptor agonist |
Approved |
250 |
Oral, alternative to eltrombopag |
Market Entry Potential for Rilzabrutinib
- Demonstrates a novel mechanism by targeting BTK, which modulates immune response, potentially reducing side effects associated with current therapies.
- Clinical Data: Phase 1/2 trials indicated a favorable safety profile and efficacy signals; phase 3 trials are pending or ongoing.
Market Entry Challenges and Opportunities
-
Challenges:
- Lengthy clinical approval process.
- Competition from established TPO receptor agonists.
- Pricing pressures from payers and insurers.
-
Opportunities:
- Potential for first-in-class BTK inhibitor in ITP, addressing unmet needs.
- May offer an oral option with a different safety profile.
- Possible expansion into other autoimmune indications such as systemic lupus erythematosus (SLE), based on BTK's role in B-cell signaling.
Price Projections
Initial Pricing Estimates:
- Oral therapies in ITP typically retail between $10,000 and $50,000 annually [2].
- For breakthrough or first-in-class drugs, premiums can push prices above this range, especially if efficacy and safety advantages exist.
| Price Point (USD/year) |
Justification |
Market Segment |
| $25,000 – $35,000 |
Comparable to current oral ITP drugs |
Competitive, aligns with existing oral therapies |
| $40,000 – $50,000 |
If safety/efficacy marks a significant advance |
Potential for premium pricing if phase 3 results are strong |
Revenue Projections (2025–2030)
| Year |
Estimated Patients (Global) |
Penetration Rate |
Estimated Sales (USD millions) |
| 2025 |
20,000 |
2% |
40 |
| 2026 |
45,000 |
5% |
112.5 |
| 2027 |
70,000 |
8% |
224 |
| 2028 |
100,000 |
12% |
480 |
| 2029 |
130,000 |
15% |
975 |
| 2030 |
150,000 |
20% |
1,500 |
Note: These projections assume successful regulatory approval, market acceptance based on clinical trial outcomes, and competitive positioning.
Pricing Strategy and Payer Considerations
- Price setting will depend on demonstrated clinical benefits, safety profile, and market acceptance.
- Payers may negotiate discounts, especially if pharmacies develop biosimilars or generics for existing therapies.
- Value-based pricing frameworks likely to be adopted, linking cost to clinical outcomes.
Regulatory Timeline and Market Entry
- Phase 3 trial results are expected within 12–18 months.
- Regulatory submission anticipated 2024.
- Market launch targeted for 2025.
- Entry delays attributable to regulatory review length or adverse trial outcomes could shift projections.
Key Differences with Competitors
- First-in-class BTK inhibitor targeting autoimmune regulation rather than TPO receptor stimulation.
- Potential for broader autoimmune disease indications.
- Oral administration offers convenience relative to injectable biologics like Nplate.
Key Takeaways
- NDC 24658-0781 (Rilzabrutinib) enters a $1.3 billion ITP market with growth driven by unmet medical needs.
- The drug's market potential hinges on positive Phase 3 data, regulatory approval, and acceptance as a safe, effective oral alternative.
- Expected launch price: $25,000–$50,000 annually, with projected sales reaching $1.5 billion by 2030.
- Competition from established TPO receptor agonists will influence pricing strategies.
- Broad autoimmune applications could expand the target market beyond ITP.
FAQs
What is the development status of NDC 24658-0781?
It is in Phase 3 clinical trials, with regulatory submission anticipated in 2024.
How does Rilzabrutinib differ from existing ITP treatments?
It targets BTK, aiming to modulate immune responses with potentially fewer side effects than immunosuppressants and offering oral administration advantages.
What are the main risks to market entry?
Delayed approval, unfavorable trial results, or inability to demonstrate clear safety and efficacy advantages.
What is the outlook for pricing strategies?
Pricing will likely be aligned with other oral ITP therapies, subject to negotiations based on clinical benefits and payer policies.
Could Rilzabrutinib expand beyond ITP?
Yes. BTK inhibitors show promise across several autoimmune and B-cell mediated conditions, creating expansion opportunities.
References
[1] U.S. Food and Drug Administration. (2022). National Drug Code Directory.
[2] Centers for Medicare & Medicaid Services. (2021). Average Wholesale Price Reports.
